This Article Full Text (PDF) All Versions of this Article: 1545109708322302v1 7/5/259    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chaudhary, M. Articles by Bhalla, P. Search for Related Content PubMed PubMed Citation Articles by Chaudhary, M. Articles by Bhalla, P. Pubmed/NCBI databases Medline Plus Health Information AIDS Medicines Social Bookmarking                         What's this?

Use of Surrogate Markers to Predict the HIV Disease Stage and Time to Initiate Antiretroviral Therapy in Developing Countries

Department of Microbiology, Maulana Azad Medical College, New Delhi, India, drmonica74@ gmail.com

Bineeta Kashyap, MBBS, MD

Department of Microbiology, Maulana Azad Medical College, New Delhi, India

Hitender Gautam, MBBS

Department of Microbiology, Maulana Azad Medical College, New Delhi, India

Sanjeev Saini, BSc, MSc

Department of Microbiology, Maulana Azad Medical College, New Delhi, India

Preena Bhalla, MBBS, MD

Department of Microbiology, Maulana Azad Medical College, New Delhi, India

CD4 counting is the standard method for determining eligibility for antiretroviral therapy (ART) and HIV disease progression, but it is not widely available in developing countries. The aim of this study was to correlate the levels of β-2 microglobulin and total lymphocyte count (TLC) with CD4 counts for monitoring disease progression and identify patients who require ART. The authors measured CD4 T-cell counts, TLC, and β-2 microglobulin levels in 119 HIV seropositive patients. There was a significant negative correlation between CD4 counts and β-2 microglobulin levels and significant positive correlation between TLC and CD4 counts. Taking a TLC cutoff of 1600 and β-2 microglobulin levels 3.5 mg/l, the authors could identify 90.4% of patients with CD4 count 200 cells/µl. These assays may allow reduction in the annual number of CD4 cell evaluation and the cost associated with monitoring the immune status of HIV-positive patients.

Key Words: b-2 microglobulin • total lymphocyte count • HIV • surrogate markers

This version was published on September 1, 2008

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 7, No. 5, 259-264 (2008)
DOI: 10.1177/1545109708322302


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?